FibroGen Q3 2025: Net loss $13.1M, China sale ~$220M, cash $121.1M into 2028

KYNTRA BIO, INC.

2025-Q3 EPS reported $48.90 vs consensus -$4.09 ▲ beat (+1297.0%)

Net loss from continuing ops $13.1M ($3.25 loss per share) vs $48.3M ($12.01 loss) YoY.
Total revenue from continuing ops $1.1M, up from $0.1M YoY.
Completed sale of FibroGen China to AstraZeneca for ~$220M ($85M enterprise + $135M net cash).
Cash, equivalents, receivables, and investments $121.1M; cash runway into 2028; repaid Morgan Stanley term loan.
Initiated Phase 2 trial of FG-3246 in mCRPC; FDA agreed on Phase 3 roxadustat design for LR-MDS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.